These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345 [TBL] [Abstract][Full Text] [Related]
4. Effects of losartan and amlodipine on urinary albumin excretion and ambulatory blood pressure in hypertensive type 2 diabetic patients with overt nephropathy. Yasuda G; Ando D; Hirawa N; Umemura S; Tochikubo O Diabetes Care; 2005 Aug; 28(8):1862-8. PubMed ID: 16043724 [TBL] [Abstract][Full Text] [Related]
5. Angiotensin II type 1 receptor gene polymorphism could influence renoprotective response to losartan treatment in type 1 diabetic patients with high urinary albumin excretion rate. Dragović T; Ajdinović B; Hrvacević R; Ilić V; Magić Z; Andelković Z; Kocev N Vojnosanit Pregl; 2010 Apr; 67(4):273-8. PubMed ID: 20465154 [TBL] [Abstract][Full Text] [Related]
6. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy. Schjoedt KJ; Lajer M; Andersen S; Tarnow L; Rossing P; Parving HH Scand J Clin Lab Invest; 2006; 66(3):173-80. PubMed ID: 16714246 [TBL] [Abstract][Full Text] [Related]
7. Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Rossing P; Tarnow L; Boelskifte S; Jensen BR; Nielsen FS; Parving HH Diabetes; 1997 Mar; 46(3):481-7. PubMed ID: 9032106 [TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037 [TBL] [Abstract][Full Text] [Related]
10. Comparative effect of lisinopril and lacidipine on urinary albumin excretion in patients with type 11 diabetic nephropathy. Salako BL; Finomo FO; Kadiri S; Arije A; Olatosin AO Afr J Med Med Sci; 2002 Mar; 31(1):53-7. PubMed ID: 12518931 [TBL] [Abstract][Full Text] [Related]
11. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Buter H; Navis G; Dullaart RP; de Zeeuw D; de Jong PE Nephrol Dial Transplant; 2001 Apr; 16(4):771-5. PubMed ID: 11274272 [TBL] [Abstract][Full Text] [Related]
12. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Andersen S; van Nieuwenhoven FA; Tarnow L; Rossing P; Rossing K; Wieten L; Goldschmeding R; Parving HH Kidney Int; 2005 Jun; 67(6):2325-9. PubMed ID: 15882275 [TBL] [Abstract][Full Text] [Related]
13. [Effect of antihypertensive combinations on arterial pressure, albuminuria, and glycemic control in patients with type II diabetic nephropathy: a randomized study]. Goicolea I; Fernández González R; Piniés J; Garrido J; Martínez JM; Armenteros S; Moreno Carretero E Nefrologia; 2002; 22(2):170-8. PubMed ID: 12085418 [TBL] [Abstract][Full Text] [Related]
14. Aliskiren combined with losartan in type 2 diabetes and nephropathy. Parving HH; Persson F; Lewis JB; Lewis EJ; Hollenberg NK; N Engl J Med; 2008 Jun; 358(23):2433-46. PubMed ID: 18525041 [TBL] [Abstract][Full Text] [Related]
15. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. Mehdi UF; Adams-Huet B; Raskin P; Vega GL; Toto RD J Am Soc Nephrol; 2009 Dec; 20(12):2641-50. PubMed ID: 19926893 [TBL] [Abstract][Full Text] [Related]
16. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317 [TBL] [Abstract][Full Text] [Related]
17. Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Schjoedt KJ; Andersen S; Rossing P; Tarnow L; Parving HH Diabetologia; 2004 Nov; 47(11):1936-9. PubMed ID: 15551047 [TBL] [Abstract][Full Text] [Related]
18. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. Agha A; Bashir K; Anwar E Nepal Med Coll J; 2007 Jun; 9(2):79-83. PubMed ID: 17899953 [TBL] [Abstract][Full Text] [Related]
19. Effect of losartan on TGF-beta1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Esmatjes E; Flores L; Iñigo P; Lario S; Ruilope LM; Campistol JM Nephrol Dial Transplant; 2001; 16 Suppl 1():90-3. PubMed ID: 11369831 [TBL] [Abstract][Full Text] [Related]
20. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Persson F; Rossing P; Schjoedt KJ; Juhl T; Tarnow L; Stehouwer CD; Schalkwijk C; Boomsma F; Frandsen E; Parving HH Kidney Int; 2008 Jun; 73(12):1419-25. PubMed ID: 18337712 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]